Autres langues Fate Therapeutics, Inc.

Actions

FATE

US31189P1021

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 26/04/2024			Varia. 5j.	Varia. 1 janv.
3,8 ^USD	-1,81 %		-20,50 %	+1,60 %

22/04	Fate Therapeutics, Inc. annonce la présentation des données de preuve de concept du FT819 pour les maladies auto-immunes médiées par les lymphocytes B lors de la réunion annuelle de l'ASGCT	CI
19/03	Fate Therapeutics fixe le prix d'une offre de 100 millions de dollars et d'un placement privé	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting	22/04
Fate Therapeutics, Inc. Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting	22/04
Fate Therapeutics Reports New Employee Inducement Award under Nasdaq Listing Rule 5635(4)	03/04
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference	03/04
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	02/04
Fate Therapeutics, Inc. announced that it has received $19.996366 million in funding from Redmile Group, LLC	21/03
Fate Therapeutics Prices $100 Million Offering, Private Placement	19/03
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement	19/03
Fate Therapeutics, Inc. announced that it expects to receive $19.996366 million in funding from Redmile Group, LLC	19/03
Fate Therapeutics, Inc.(NasdaqGM:FATE) added to S&P Biotechnology Select Industry Index	18/03
Fate Therapeutics Reports New Employee Inducement Award under Nasdaq Listing Rule 5635(4)	06/03
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	05/03
Fate Therapeutics to Present at Upcoming March Investor Conferences	04/03
Fate Therapeutics to Present at Upcoming March Investor Conferences	01/03
Fate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/02
Fate Therapeutics: Q4 Earnings Snapshot	26/02
Earnings Flash (FATE) FATE THERAPEUTICS Posts Q4 Revenue $1.7M, vs. Street Est of $1.5M	26/02
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates	26/02
Fate Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26/02
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results	15/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Fate Therapeutics, Inc.

Actions

FATE

US31189P1021

Autres langues

Filtres